• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 4, 2019

View Archived Issues

Titan's Probuphine sales buoyed by relaunch efforts

Shares of Titan Pharmaceuticals Inc. (NASDAQ:TTNP) climbed 34.2 percent to close at $1.65 on Friday after the drugmaker heralded a double-digit increase in shipments of its implantable opioid addiction maintenance product, Probuphine (buprenorphine). Titan, which regained U.S. and Canadian commercial rights to Probuphine from Braeburn Inc. in May 2018, attributed the improvement in part to its recruitment of new commercial and medical affairs personnel, its re-engagement with prescribers and efforts to better identify areas where it can be most successful. Read More

First homegrown DPP-4 inhibitor gets China nod

HONG KONG – Chinese drug regulators have granted the first marketing clearance to a homegrown dipeptidyl peptidase-4 (DPP-4) inhibitor for treating type 2 diabetes, developed by Jiangsu Aosaikang Pharmaceutical Co. Ltd. The saxagliptin tablet, which comes in 5 mg or 2.5 mg, is registered as a category IV chemical drug – a generic with equivalent quality and efficacy to the originator's drugs that are already marketed in China. Read More

Biopharma sector rebounds off its dismal December performance with solid January

The biopharmaceutical sector has quickly rebounded after its dismal December performance, where it shed almost 8 percent in valuation, and it hasn't taken long for biotech investors to shake off their bear mindset. In fact, they have been generally more upbeat following the 37th Annual J.P. Morgan Healthcare Conference. As a result, the BioWorld Biopharmaceutical index outpaced the general markets and recouped its loss and then some and returned a significant 10 percent gain in value in January, compared with the Dow Jones Industrial Average, which gained 7 percent. (See BioWorld Biopharmaceutical index, below.) Read More

Therapy paradigm shifts, Epizyme timelines altered; FL to occupy center stage?

Epizyme Inc. recently charmed investors by disclosing its brisker path forward with EZH2 inhibitor tazemetostat in follicular lymphoma (FL), and drew more attention to the subtype of non-Hodgkin lymphoma (NHL). Read More

Talk of removing safe harbor for rebates advances to proposed rule

After months of talking about doing away with the current rebate system, Health and Human Services (HHS) Secretary Alex Azar proposed a rule late Thursday that removes the safe harbor for drug manufacturer rebates paid to pharmacy benefit managers (PBMs). Read More

Other news to note

Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it received notice from the NYSE American LLC that the company was granted an extension to March 31 to regain compliance with listing standards. Read More

Financings

Cancer Genetics Inc., of Rutherford, N.J., said it closed its public offering of about 15.2 million shares priced at 23 cents each. Gross proceeds totaled about $3.5 million. H.C. Wainwright & Co. acted as the sole placement agent. Read More

Clinical data for Feb. 1, 2019

Read More

Regulatory actions for Feb. 1, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe